US20110201654A1 - Therapeutic combination - Google Patents

Therapeutic combination Download PDF

Info

Publication number
US20110201654A1
US20110201654A1 US13/091,622 US201113091622A US2011201654A1 US 20110201654 A1 US20110201654 A1 US 20110201654A1 US 201113091622 A US201113091622 A US 201113091622A US 2011201654 A1 US2011201654 A1 US 2011201654A1
Authority
US
United States
Prior art keywords
atorvastatin
amlodipine
pharmaceutically acceptable
amount
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/091,622
Inventor
Robert Anderw Donald Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22009597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110201654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/091,622 priority Critical patent/US20110201654A1/en
Publication of US20110201654A1 publication Critical patent/US20110201654A1/en
Priority to US13/445,339 priority patent/US20120208854A1/en
Priority to US13/743,897 priority patent/US20130131125A1/en
Priority to US14/049,286 priority patent/US20140039017A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to pharmaceutical combinations of amlodipine and pharmaceutically acceptable acid addition salts thereof and atorvastatin and pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans.
  • This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms or signs of cardiac risk, including humans.
  • HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
  • mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase.
  • Statins inhibit HMG-CoA reductase from catalyzing this conversion. As such, statins are collectively potent lipid lowering agents.
  • Atorvastatin calcium disclosed in U.S. Pat. No. 5,273,995, which is incorporated herein by reference, is currently sold as Lipitor® and has the formula
  • Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA.
  • atorvastatin calcium is a potent lipid lowering compound.
  • the free carboxylic acid form of atorvastatin exists predominantly as the lactone of the formula
  • Amlodipine and related dihydropyridine compounds are disclosed in U.S. Pat. No. 4,572,909, which is incorporated herein by reference, as potent anti-ischemic and antihypertensive agents.
  • U.S. Pat. No. 4,879,303 which is incorporated herein by reference, discloses amlodipine benzenesulfonate salt (also termed amlodipine besylate).
  • Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.
  • amlodipine, amlodipine besylate and other pharmaceutically acceptable acid addition salts of amlodipine have utility as antihypertensive agents and as antiischemic agents.
  • Amlodipine and its pharmaceutically acceptable acid addition salts are also disclosed in U.S. Pat. No. 5,155,120 as having utility in the treatment of congestive heart failure.
  • Amlodipine besylate is currently sold as Norvasc®.
  • Amlodipine has the formula
  • Atherosclerosis is a condition characterized by irregularly distributed lipid deposits in the intima of arteries, including coronary, carotid and peripheral arteries.
  • Atherosclerotic coronary heart disease (hereinafter termed “CHD”) accounts for 53% of all deaths attributable to a cardiovascular event.
  • CHD accounts for nearly one-half (about $50-60 billion) of the total U.S. cardiovascular healthcare expenditures and about 6% of the overall national medical bill each year.
  • CHD remains the most common cause of death in the United States.
  • HMG-CoA reductase 3-hydroxy-3-methylglutaryl-coenzyme A reductase
  • LDL-C low density lipoprotein cholesterol
  • Angina pectoris is a severe constricting pain in the chest, often radiating from the precordium to the left shoulder and down the left arm. Often angina pectoris is due to ischemia of the heart and is usually caused by coronary disease.
  • symptomatic angina pectoris varies significantly from country to country.
  • patients who present with symptomatic, stable angina pectoris are frequently treated with surgical procedures or PTCA.
  • Patients who undergo PTCA or other surgical procedures designed to treat angina pectoris frequently experience complications such as restenosis.
  • This restenosis may be manifested either as a short term proliferative response to angioplasty-induced trauma or as long term progression of the atherosclerotic process in both graft vessels and angioplastied segments.
  • NASH National Cholesterol Education Program
  • Amlodipine helps to prevent myocardial ischemia in patients with exertional angina pectoris by reducing Total Peripheral Resistance, or afterload, which reduces the rate pressure product and thus myocardial oxygen demand at any particular level of exercise.
  • amlodipine has been demonstrated to block constriction and thus restore myocardial oxygen supply. Further, amlodipine has been shown to increase myocardial oxygen supply by dilating the coronary arteries.
  • Hypertension frequently coexists with hyperlipidemia and both are considered to be major risk factors for developing cardiac disease ultimately resulting in adverse cardiac events. This clustering of risk factors is potentially due to a common mechanism. Further, patient compliance with the management of hypertension is generally better than patient compliance with hyperlipidemia. It would therefore be advantageous for patients to have a single therapy which treats both of these conditions.
  • Coronary heart disease is a multifactorial disease in which the incidence and severity are affected by the lipid profile, the presence of diabetes and the sex of the subject. Incidence is also affected by smoking and left ventricular hypertrophy which is secondary to hypertension. To meaningfully reduce the risk of coronary heart disease, it is important to manage the entire risk spectrum. For example, hypertension intervention trials have failed to demonstrate full normalization in cardiovascular mortality due to coronary heart disease. Treatment with cholesterol synthesis inhibitors in patients with and without coronary artery disease reduces the risk of cardiovascular morbidity and mortality.
  • Modeled incidence rates range from less than 1% to greater than 80% over an arbitrarily selected six year interval. However, these rates are typically less than 10% and rarely exceed 45% in men and 25% in women.
  • composition A comprising:
  • composition AA of Composition A comprising amlodipine besylate.
  • composition AB a pharmaceutical composition
  • Composition AA comprising the hemicalcium salt of atorvastatin.
  • composition B a first pharmaceutical composition
  • Composition B for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition BA a first pharmaceutical composition, hereinafter termed “Composition BA”, of Composition B wherein said second pharmaceutical composition comprises amlodipine besylate.
  • composition BB a first pharmaceutical composition, hereinafter termed “Composition BB”, of Composition BA comprising the hemicalcium salt of atorvastatin.
  • composition C a first pharmaceutical composition, hereinafter termed “Composition C”, for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition CA a first pharmaceutical composition, hereinafter termed “Composition CA”, of Composition C comprising amlodipine besylate.
  • composition CB a first pharmaceutical composition, hereinafter termed “Composition CB”, of Composition CA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition D a first pharmaceutical composition
  • Composition D for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition DA a first pharmaceutical composition, hereinafter termed “Composition DA”, of Composition D comprising amlodipine besylate.
  • composition DB a first pharmaceutical composition
  • said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition E a first pharmaceutical composition
  • Composition E for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition EA a first pharmaceutical composition, hereinafter termed “Composition EA”, of Composition E wherein said second pharmaceutical composition comprises amlodipine besylate.
  • composition EB of Composition EA comprising the hemicalcium salt of atorvastatin.
  • composition F a first pharmaceutical composition
  • Composition F a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition FA a first pharmaceutical composition, hereinafter termed “Composition FA”, of Composition F comprising amlodipine besylate.
  • composition FB a first pharmaceutical composition
  • said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition G a first pharmaceutical composition, hereinafter termed “Composition G”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • Composition G a first pharmaceutical composition for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition
  • composition GA a first pharmaceutical composition, hereinafter termed “Composition GA”, of Composition G wherein said second pharmaceutical composition comprises amlodipine besylate.
  • composition GB a first pharmaceutical composition, hereinafter termed “Composition GB”, of Composition G comprising the hemicalcium salt of atorvastatin.
  • composition H a first pharmaceutical composition, hereinafter termed “Composition H”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent. acceptable carrier or diluent.
  • composition HA a first pharmaceutical composition, hereinafter termed “Composition HA”, of Composition H comprising amlodipine besylate.
  • composition HB a first pharmaceutical composition
  • said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition J a first pharmaceutical composition
  • Composition J a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition JA a first pharmaceutical composition, hereinafter termed “Composition JA”, of Composition J wherein said second pharmaceutical composition comprises amlodipine besylate.
  • composition JB a first pharmaceutical composition
  • Composition JA comprising the hemicalcium salt of atorvastatin.
  • composition K a first pharmaceutical composition, hereinafter termed “Composition K”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition KA a first pharmaceutical composition
  • second pharmaceutical composition comprises amlodipine besylate
  • composition KB a first pharmaceutical composition, hereinafter termed “Composition KB”, of Composition KA comprising the hemicalcium salt of atorvastatin.
  • composition KC composition KB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition KC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • composition KD a composition, hereinafter termed “Composition KD”, of Composition KB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • composition L a first pharmaceutical composition, hereinafter termed “Composition L”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition LA a first pharmaceutical composition, hereinafter termed “Composition LA”, of Composition L comprising amlodipine besylate.
  • composition LB a first pharmaceutical composition
  • said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition LB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • composition LD a composition, hereinafter termed “Composition LD”, of Composition LB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • composition M a first pharmaceutical composition, hereinafter termed “Composition M”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition MA a first pharmaceutical composition, hereinafter termed “Composition MA”, of Composition M comprising amlodipine besylate.
  • composition MB a first pharmaceutical composition, hereinafter termed “Composition MB”, of Composition MA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition MC a composition, hereinafter termed “Composition MC”, of Composition MB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • composition MD a composition, hereinafter termed “Composition MD”, of Composition MB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • composition N a first pharmaceutical composition, hereinafter termed “Composition N”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition NA a first pharmaceutical composition, hereinafter termed “Composition NA”, of Composition N wherein said second pharmaceutical composition comprises amlodipine besylate.
  • composition NB a first pharmaceutical composition
  • Composition NA comprising the hemicalcium salt of atorvastatin
  • composition NC a composition, hereinafter termed “Composition NC”, of Composition NB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • composition ND a composition, hereinafter termed “Composition ND”, of Composition NB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • composition P a first pharmaceutical composition, hereinafter termed “Composition P”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • Composition P a first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlo
  • composition PA a first pharmaceutical composition, hereinafter termed “Composition PA”, of Composition P comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition PA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition Q a first pharmaceutical composition, hereinafter termed “Composition Q”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • Composition Q a first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of
  • composition QA a first pharmaceutical composition, hereinafter termed “Composition QA”, of Composition Q wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition QA comprising the hemicalcium salt of atorvastatin.
  • composition R a first pharmaceutical composition, hereinafter termed “Composition R”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • Composition R a first pharmaceutical composition for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutical
  • composition RA a first pharmaceutical composition, hereinafter termed “Composition RA”, of Composition R comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition RA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • composition S a first pharmaceutical composition
  • Composition S for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • composition SA a first pharmaceutical composition, hereinafter termed “Composition SA”, of Composition S wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition S comprising the hemicalcium salt of atorvastatin.
  • Kit A for achieving a therapeutic effect in a mammal comprising:
  • Kit AA of Kit A comprising amlodipine besylate.
  • Kit AB a kit, hereinafter termed “Kit AB”, of Kit AA comprising the hemicalcium salt of atorvastatin.
  • Kit AC a kit, hereinafter termed “Kit AC”, of Kit AB wherein said therapeutic effect is treatment of hypertension and hyperlipidemia.
  • Kit AD Kit AB wherein said therapeutic effect is treatment of angina pectoris.
  • Kit AE Kit AB wherein said therapeutic effect is management of cardiac risk.
  • Kit AF Kit AB wherein said therapeutic effect is treatment of atherosclerosis.
  • Kit AG a kit, hereinafter termed “Kit AG”, of Kit AF wherein said treatment of atherosclerosis slows the progression of atherosclerotic plaques.
  • Kit AH a kit, hereinafter termed “Kit AH”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • Kit AJ a kit, hereinafter termed “Kit AJ”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • Kit AG a kit, hereinafter termed “Kit AK”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • Kit AF a kit, hereinafter termed “Kit AL”, of Kit AF wherein said treatment of atherosclerosis causes the regression of atherosclerotic plaques.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • Method A for treating a mammal in need of therapeutic treatment comprising administering to said mammal
  • This invention is particularly directed to a method, hereinafter Method B, of Method A comprising amlodipine besylate.
  • Method C of Method B comprising the hemicalcium salt of atorvastatin.
  • Method D This invention is still more particularly directed to a method, hereinafter termed “Method D”, of Method A wherein said first compound and said second compound are administered simultaneously.
  • Method E This invention is still more particularly directed to a method, hereinafter termed “Method E”, of Method A wherein said first compound and said second compound are administered sequentially in either order.
  • Method F This invention is also particularly directed to a method, hereinafter termed “Method F”, of Method C wherein said first compound and said second compound are administered simultaneously.
  • Method G This invention is further directed to a method, hereinafter termed “Method G”, of Method C wherein said first compound and said second compound are administered sequentially in either order.
  • This invention is still further directed to a method of Method A wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is still further directed to a method of Method F wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is still further directed to a method of Method G wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • Amlodipine is a racemic compound due to the symmetry at position 4 of the dihydropyridine ring.
  • the R and S enantiomers may be prepared as described by Arrowsmith et al., J. Med. Chem., 1986, 29, 1696.
  • the calcium channel blocking activity of amlodipine is substantially confined to the S( ⁇ ) isomer and to the racemic mixture containing the R(+) and S( ⁇ ) forms. (see International Patent Application Number PCT/EP94/02697).
  • the R(+) isomer has little or no calcium channel blocking activity. However, the R(+) isomer is a potent inhibitor of smooth muscle cell migration. Thus, the R(+) isomer is useful in the treatment or prevention of atherosclerosis.
  • cardiac risk means the likelihood that a subject will suffer a future adverse cardiac event such as, e.g., myocardial infarction, cardiac arrest, cardiac failure, cardiac ischaemia. Cardiac risk is calculated using the Framingham Risk Equation as set forth above. The term “cardiac risk management” means that the risk of future adverse cardiac events is substantially reduced.
  • compositions of this invention comprise amlodipine or a pharmaceutically acceptable acid addition salt thereof and/or atorvastatin or a pharmaceutically acceptable salt thereof.
  • Amlodipine may readily be prepared as described in U.S. Pat. No. 4,572,909 which is incorporated herein by reference.
  • Amlodipine besylate which is currently sold as Norvasc®, may be prepared as described in U.S. Pat. No. 4,879,303, which is incorporated herein by reference.
  • Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.
  • salts are intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, besylate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • amlodipine may be prepared by reacting the free base form of amlodipine with the appropriate acid.
  • the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate)
  • the hydrogen form of a dibasic acid e.g., the hydrogen sulfate, the succinate
  • the dihydrogen form of a tribasic acid e.g., the dihydrogen phosphate, the citrate
  • at least one molar equivalent and usually a molar excess of the acid is employed.
  • salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate
  • the appropriate and exact chemical equivalents of acid will generally be used.
  • the free base of amlodipine and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • Atorvastatin may readily be prepared as described in U.S. Pat. No. 4,681,892, which is incorporated herein by reference.
  • the hemicalcium salt of atorvastatin, which is currently sold as Lipitor®, may readily be prepared as described in U.S. Pat. No. 5,273,995, which is incorporated herein by reference.
  • pharmaceutically acceptable salts includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts.
  • pharmaceutically-acceptable cationic salts is intended to define but is not limited to such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g.
  • benzathine N,N ⁇ -dibenzylethylenediamine
  • choline diethanolamine
  • ethylenediamine meglumine (N-methylglucamine)
  • benethamine N-benzylphenethylamine
  • diethylamine piperazine
  • tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine.
  • salts are intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • atorvastatin may be readily prepared by reacting the free acid form of atorvastatin with an appropriate base, usually one equivalent, in a co-solvent.
  • bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine.
  • the salt is isolated by concentration to dryness or by addition of a non-solvent.
  • salts are preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (e.g., sodium or potassium ethylhexanoate, magnesium oleate) and employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates.
  • a solution of a different salt of the cation e.g., sodium or potassium ethylhexanoate, magnesium oleate
  • a solvent e.g., ethyl acetate
  • the acid addition salts of atorvastatin may be readily prepared by reacting the free base form of atorvastatin with the appropriate acid.
  • the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate)
  • the hydrogen form of a dibasic acid e.g., the hydrogen sulfate, the succinate
  • the dihydrogen form of a tribasic acid e.g., the dihydrogen phosphate, the citrate
  • at least one molar equivalent and usually a molar excess of the acid is employed.
  • salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate
  • the appropriate and exact chemical equivalents of acid will generally be used.
  • the free base and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • amlodipine, pharmaceutically acceptable acid addition salts thereof, atorvastatin and pharmaceutically acceptable salts thereof may occur as hydrates or solvates. Said hydrates and solvates are also within the scope of the invention.
  • the pharmaceutical combinations and methods of this invention are all adapted to therapeutic use as agents in the treatment of atherosclerosis, angina pectoris, and a condition characterized by the presence of both hypertension and hyperlipidemia in mammals, particularly humans. Further, since these diseases and conditions are closely related to the development of cardiac disease and adverse cardiac conditions, these combinations and methods, by virtue of their action as antiatherosclerotics, antianginals, antihypertensives and antihyperlipidemics, are useful in the management of cardiac risk.
  • This study is a prospective randomized evaluation of the effect of a combination of amlodipine and atorvastatin on the progression/regression of coronary and carotid artery disease.
  • the study is used to show that a combination of amlodipine and atorvastatin is effective in slowing or arresting the progression or causing regression of existing coronary artery disease (CAD) as evidenced by changes in coronary angiography or carotid ultrasound, in subjects with established disease.
  • CAD coronary artery disease
  • This study is an angiographic documentation of coronary artery disease carried out as a double-blind, placebo-controlled trial of a minimum of about 500 subjects and preferably of about 780 to about 1200 subjects. It is especially preferred to study about 1200 subjects in this study. Subjects are admitted into the study after satisfying certain entry criteria set forth below.
  • Subjects accepted for entry into this trial must satisfy certain criteria. Thus the subject must be an adult, either male or female, aged 18-80 years of age in whom coronary angiography is clinically indicated. Subjects will have angiographic presence of a significant focal lesion such as 30% to 50% on subsequent evaluation by quantitative coronary angiography (QCA) in a minimum of one segment (non-PTCA, non-bypassed or non-MI vessel) that is judged not likely to require intervention over the next 3 years. It is required that the segments undergoing analysis have not been interfered with. Since percutaneous transluminal cardiac angioplasty (PTCA) interferes with segments by the insertion of a balloon catheter, non-PTCA segments are required for analysis.
  • PTCA percutaneous transluminal cardiac angioplasty
  • segment to be analyzed have not suffered a thrombotic event, such as a myocardial infarct (MI).
  • MI myocardial infarct
  • Segments that will be analyzed include: left main, proximal, mid and distal left anterior descending, first and second diagonal branch, proximal and distal left circumflex, first or largest space obtuse marginal, proximal, mid and distal right coronary artery.
  • Subjects will have an ejection fraction of greater than 30% determined by catheterization or radionuclide ventriculography or ECHO cardiogram at the time of the qualifying angiogram or within the previous three months of the acceptance of the qualifying angiogram provided no intervening event such as a thrombotic event or procedure such as PTCA has occurred.
  • the study is carried out at multiple sites.
  • subjects undergo quantitative coronary angiography as well as B-mode carotid artery ultrasonography and assessment of carotid arterial compliance at designated testing centers. This establishes baselines for each subject.
  • subjects are randomized to receive amlodipine besylate (10 mgs) and placebo or atorvastatin calcium (80 mgs) and placebo or amlodipine besylate (10 mgs) and atorvastatin calcium (80 mgs). All doses set forth in this protocol are per day doses. The amount of amlodipine besylate may be varied as required.
  • a subject will start out taking 10 mg and the amount will be titrated down to as little as 5 mg as determined by the clinical physician.
  • the amount of atorvastatin calcium will similarly be titrated down from 80 mg if it is determined by the physician to be in the best interests of the subject.
  • the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • the subjects are monitored for a one to three year period, generally three years being preferred.
  • B-mode carotid ultrasound assessment of carotid artery atherosclerosis and compliance are performed at regular intervals throughout the study.
  • cortiography is performed at the conclusion of the one to three year treatment period.
  • the baseline and post-treatment angiograms and the intervening carotid artery B-mode ultrasonograms are evaluated for new lesions or progression of existing atherosclerotic lesions.
  • Arterial compliance measurements are assessed for changes from baseline and over the 6-month evaluation periods.
  • the primary objective of this study is to show that the combination of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof reduces the progression of atherosclerotic lesions as measured by quantitative coronary angiography (QCA) in subjects with clinical coronary artery disease.
  • QCA measures the opening in the lumen of the arteries measured.
  • the primary endpoint of the study is the change in the average mean segment diameter of the coronary artery tree.
  • the diameter of an arterial segment is measured at various portions along the length of that segment.
  • the average diameter of that segment is then determined.
  • the average of all segment averages is determined to arrive at the average mean segment diameter.
  • the mean segment diameter of subjects taking atorvastatin or pharmaceutically acceptable salts thereof and amlodipine or pharmaceutically acceptable acid addition salts thereof will decline more slowly, will be halted completely, or there will be an increase in the mean segment diameter.
  • the secondary objective of this study is to show that the combination of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically salt thereof reduces the rate of progression of atherosclerosis in the carotid arteries as measured by the slope of the maximum intimal-medial thickness measurements averaged over 12 separate wall segments (Mean Max) as a function of time, more than does amlodipine or a pharmaceutically acceptable acid addition salt thereof or atorvastatin or a pharmaceutically acceptable salt thereof alone.
  • the intimal-medial thickness of subjects taking atorvastatin or a pharmaceutically acceptable salt thereof and amlodipine or a pharmaceutically acceptable acid addition salt thereof will increase more slowly, will cease to increase or will decrease.
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in the treatment of symptomatic angina.
  • Subjects are males or females between 18 and 80 years of age with a history of typical chest pain associated with one of the following objective evidences of cardiac ischemia: (1) stress test segment elevation of about one millimeter or more from the ECG; (2) positive treadmill stress test; (3) new wall motion abnormality on ultrasound; or (4) coronary angiogram with a significant qualifying stenosis. Generally a stenosis of about 30-50% is considered to be significant.
  • Each subject is evaluated for about ten to thirty-two weeks. At least ten weeks are generally required to complete the study. Sufficient subjects are used in this screen to ensure that about 200 to 800 subjects and preferably about 400 subject are evaluated to complete the study. Subjects are screened for compliance with the entry criteria, set forth below, during a four week run in phase. After the screening criteria are met, subjects are washed out from their current anti-anginal medication and stabilized on a long acting nitrate such as, for example, nitroglycerin, isosorbide-5-mononitrate or isosorbide dinitrate. The term “washed out”, when used in connection with this screen, means the withdrawal of current anti-anginal medication so that substantially all of said medication is eliminated from the body of the subject.
  • a long acting nitrate such as, for example, nitroglycerin, isosorbide-5-mononitrate or isosorbide dinitrate.
  • a period of eight weeks is preferably allowed for both the wash out period and for the establishment of the subject on stable doses of said nitrate.
  • Subjects having one or two attacks of angina per week while on stable doses of long acting nitrate are generally permitted to skip the wash out phase.
  • the subjects enter the randomization phase provided the subjects continue to have either one or two angina attacks per week.
  • the subjects are randomly placed into one of the four arms of the study set forth below.
  • ECG electrocardiogram
  • exercise stress testing such as a treadmill
  • PET photon emission tomography
  • subjects are initiated on one of the following four arms of the study: (1) placebo; (2) atorvastatin calcium (about 2.5 mg to about 160 mg); (3) amlodipine besylate (about 2.5 mg to about 20 mg); or (4) a combination of the above doses of amlodipine besylate and atorvastatin calcium together.
  • the subjects are then monitored for two to twenty four weeks.
  • the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • subjects will undergo the following investigations: (1) twenty four hour ambulatory ECG, such as Holter monitoring; (2) exercise stress testing (e.g. treadmill using said modified Bruce Protocol); and (3) evaluation of myocardial perfusion using PET scanning.
  • ECG electronic cardiac record
  • exercise stress testing e.g. treadmill using said modified Bruce Protocol
  • evaluation of myocardial perfusion using PET scanning Patients keep a diary of painful ischemic events and nitroglycerine consumption. It is generally desirable to have an accurate record of the number of anginal attacks suffered by the patient during the duration of the test. Since a patient generally takes nitroglycerin to ease the pain of an anginal attack, the number of times that the patient administers nitroglycerine provides a reasonably accurate record of the number of anginal attacks.
  • the person conducting the test will evaluate the subject using the tests described. Successful treatment will yield fewer instances of ischemic events as detected by ECG, will allow the subject to exercise longer or at a higher intensity level on the treadmill, or to exercise without pain on the treadmill, or will yield better perfusion or fewer perfusion defects on photoemission tomography (PET).
  • PET photoemission tomography
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in controlling both hypertension and hyperlipidemia in subjects who have mild, moderate, or severe hypertension and hyperlipidemia.
  • Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are used in this screen to ensure that about 400 to 800 subjects are evaluated to complete the study.
  • Subjects are male or female adults between 18 and 80 years of age having both hyperlipidemia and hypertension. The presence of hyperlipidemia is evidenced by evaluation of the low density lipoprotein (LDL) level of the subject relative to certain positive risk factors. If the subject has no coronary heart disease (CHD) and has less than two positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 190. If the subject has no CHD and has two or more positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 160. If the subject has CHD, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 130.
  • LDL low density lipoprotein
  • Positive risk factors include (1) male over 45, (2) female over 55 wherein said female is not undergoing hormone replacement therapy (HRT), (3) family history of premature cardiovascular disease, (4) the subject is a current smoker, (5) the subject has diabetes, (6) an HDL of less than 45, and (7) the subject has hypertension.
  • An HDL of greater than 60 is considered a negative risk factor and will offset one of the above mentioned positive risk factors.
  • BP diastolic blood pressure
  • All blood pressures are generally determined as the average of three measurements taken five minutes apart.
  • Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, subjects are washed out from their current antihypertensive and lipid lowering medication and are placed on the NCEP ATP II Step 1 diet.
  • the NCEP ATP II (adult treatment panel, 2nd revision) Step 1 diet sets forth the amount of saturated and unsaturated fat which can be consumed as a proportion of the total caloric intake.
  • the term “washed out” where used in connection with this screen, means the withdrawal of current antihypertensive and lipid lowering medication so that substantially all of said medication is eliminated from the body of the subject. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP Step 1 diet.
  • the fasting lipid screen determines baseline lipid levels in the fasting state of a subject. Generally, the subject abstains from food for twelve hours, at which time lipid levels are measured.
  • a fixed dose of amlodipine besylate generally about 2.5 to 10 mg
  • a fixed dose of atorvastatin calcium generally about 10 to 80 mg
  • a combination of the above doses of amlodipine besylate and atorvastatin calcium together. Subjects remain on these doses for a minimum of six weeks, and generally for no more than eight weeks. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention.
  • Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • the subjects return to the testing center at the conclusion of the six to eight weeks so that the baseline evaluations can be repeated.
  • the blood pressure of the subject at the conclusion of the study is compared with the blood pressure of the subject upon entry.
  • the lipid screen measures the total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apoB, VLDL (very low density lipoprotein) and other components of the lipid profile of the subject. Improvements in the values obtained after treatment relative to pretreatment values indicate the utility of the drug combination.
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination are effective in reducing the overall calculated risk of future events in subjects who are at risk for having future cardiovascular events.
  • This risk is calculated by using the Framingham Risk Equation.
  • a subject is considered to be at risk of having a future cardiovascular event if that subject is more than one standard deviation above the mean as calculated by the Framingham Risk Equation.
  • the study is used to evaluate the efficacy of a fixed combination of amlodipine and atorvastatin in controlling cardiovascular risk by controlling both hypertension and hyperlipidemia in patients who have both mild to moderate hypertension and hyperlipidemia.
  • Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are recruited to ensure that about 400 to 800 subjects are evaluated to complete the study.
  • Subjects included in the study are male or female adult subjects between 18 and 80 years of age with a baseline five year risk which risk is above the median for said subject's age and sex, as defined by the Framingham Heart Study, which is an ongoing prospective study of adult men and women showing that certain risk factors can be used to predict the development of coronary heart disease.
  • the age, sex, systolic and diastolic blood pressure, smoking habit, presence or absence of carbohydrate intolerance, presence or absence of left ventricular hypertrophy, serum cholesterol and high density lipoprotein (HDL) of more than one standard deviation above the norm for the Framingham Population are all evaluated in determining whether a patient is at risk for adverse cardiac event.
  • the values for the risk factors are inserted into the Framingham Risk equation and calculated to determine whether a subject is at risk for a future cardiovascular event.
  • Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, patients are washed out from their current antihypertensive and lipid lowering medication and any other medication which will impact the results of the screen. The patients are then placed on the NCEP ATP II Step 1 diet, as described above. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP ATP II Step 1 diet. After the four week wash out and diet stabilization period, subjects undergo the following baseline investigations: (1) blood pressure; (2) fasting; (3) lipid screen; (4) glucose tolerance test; (5) ECG; and (6) cardiac ultrasound. These tests are carried out using standard procedures well known to persons skilled in the art. The ECG and the cardiac ultrasound are generally used to measure the presence or absence of left ventricular hypertrophy.
  • dosage amounts and other dosage amounts set forth elsewhere in the specification and in the appendant claims are for an average human subject having a weight of about 65 kg to about 70 kg.
  • the skilled practitioner will readily be able to determine the dosage amount required for a subject whose weight falls outside the 65 kg to 70 kg range, based upon the medical history of the subject and the presence of diseases, e.g., diabetes, in the subject.
  • All doses set forth herein, and in the appendant claims, are daily doses.
  • amlodipine besylate is generally administered in a dosage of about 2.5 mg to about 20 mg.
  • amlodipine besylate is administered in a dosage of about 5 mg to about 10 mg.
  • the free base form or other salt forms of amlodipine besylate may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • atorvastatin is administered in a dosage of about 2.5 mg to about 160 mg.
  • atorvastatin is administered in a dosage of about 10 mg to about 80 mg.
  • the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of atorvastatin calcium is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • the compounds of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable carrier or diluent.
  • a pharmaceutically acceptable carrier or diluent e.g., a pharmaceutically acceptable styrene, aminoethyl styrene, aminoethyl sulfate, aminoethyl, a pharmaceutically acceptable carrier or diluent.
  • the compounds of this invention can be administered either individually or together in any conventional oral, parenteral or transdermal dosage form.
  • a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like.
  • Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • the combination of this invention may also be administered in a controlled release formulation such as a slow release or a fast release formulation.
  • a controlled release formulation such as a slow release or a fast release formulation.
  • Such controlled release dosage formulations of the combination of this invention may be prepared using methods well known to those skilled in the art. The method of preferred administration will be determined by the attendant physician or other person skilled in the art after an evaluation of the subject's condition and requirements.
  • the generally preferred formulation of amlodipine is Norvasc®.
  • the generally preferred formulation of atorvastatin is Lipitor®.
  • solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts.
  • aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
  • the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
  • compositions according to the invention may contain 0.1%-95% of the compound(s) of this invention, preferably 1%-70%.
  • the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the condition or disease of the subject being treated.
  • the kit includes two separate pharmaceutical compositions: amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof.
  • the kit includes container means for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container.
  • the kit includes directions for the administration of the separate components.
  • the kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.

Abstract

This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Description

  • This invention relates to pharmaceutical combinations of amlodipine and pharmaceutically acceptable acid addition salts thereof and atorvastatin and pharmaceutically acceptable salts thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those additive and synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms or signs of cardiac risk, including humans.
  • BACKGROUND OF THE INVENTION
  • The conversion of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate is an early and rate-limiting step in the cholesterol biosynthetic pathway. This step is catalyzed by the enzyme HMG-CoA reductase. Statins inhibit HMG-CoA reductase from catalyzing this conversion. As such, statins are collectively potent lipid lowering agents.
  • Atorvastatin calcium, disclosed in U.S. Pat. No. 5,273,995, which is incorporated herein by reference, is currently sold as Lipitor® and has the formula
  • Figure US20110201654A1-20110818-C00001
  • Atorvastatin calcium is a selective, competitive inhibitor of HMG-CoA. As such, atorvastatin calcium is a potent lipid lowering compound. The free carboxylic acid form of atorvastatin exists predominantly as the lactone of the formula
  • Figure US20110201654A1-20110818-C00002
  • and is disclosed in U.S. Pat. No. 4,681,893, which is incorporated herein by reference.
  • Amlodipine and related dihydropyridine compounds are disclosed in U.S. Pat. No. 4,572,909, which is incorporated herein by reference, as potent anti-ischemic and antihypertensive agents. U.S. Pat. No. 4,879,303, which is incorporated herein by reference, discloses amlodipine benzenesulfonate salt (also termed amlodipine besylate). Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers. As such, amlodipine, amlodipine besylate and other pharmaceutically acceptable acid addition salts of amlodipine have utility as antihypertensive agents and as antiischemic agents. Amlodipine and its pharmaceutically acceptable acid addition salts are also disclosed in U.S. Pat. No. 5,155,120 as having utility in the treatment of congestive heart failure. Amlodipine besylate is currently sold as Norvasc®. Amlodipine has the formula
  • Figure US20110201654A1-20110818-C00003
  • Atherosclerosis is a condition characterized by irregularly distributed lipid deposits in the intima of arteries, including coronary, carotid and peripheral arteries. Atherosclerotic coronary heart disease (hereinafter termed “CHD”) accounts for 53% of all deaths attributable to a cardiovascular event. CHD accounts for nearly one-half (about $50-60 billion) of the total U.S. cardiovascular healthcare expenditures and about 6% of the overall national medical bill each year. Despite attempts to modify secondary risk factors such as, inter alia, smoking, obesity and lack of exercise, and treatment of dyslipidemia with dietary modification and drug therapy, CHD remains the most common cause of death in the United States.
  • High levels of blood cholesterol and blood lipids are conditions involved in the onset of atherosclerosis. It is well known that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) are effective in lowering the level of blood plasma cholesterol, especially low density lipoprotein cholesterol (LDL-C), in man (Brown and Goldstein, New England Journal of Medicine, 1981, 305, No. 9, 515-517). It has now been established that lowering LDL-C levels affords protection from coronary heart disease (see, e.g., The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 1994, 344, 1383-89; and Shepherd, J. et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, New England Journal of Medicine, 1995, 333, 1301-07).
  • Angina pectoris is a severe constricting pain in the chest, often radiating from the precordium to the left shoulder and down the left arm. Often angina pectoris is due to ischemia of the heart and is usually caused by coronary disease.
  • Currently the treatment of symptomatic angina pectoris varies significantly from country to country. In the U.S., patients who present with symptomatic, stable angina pectoris are frequently treated with surgical procedures or PTCA. Patients who undergo PTCA or other surgical procedures designed to treat angina pectoris frequently experience complications such as restenosis. This restenosis may be manifested either as a short term proliferative response to angioplasty-induced trauma or as long term progression of the atherosclerotic process in both graft vessels and angioplastied segments.
  • The symptomatic management of angina pectoris involves the use of a number of drugs, frequently as a combination of two or more of the following classes: beta blockers, nitrates and calcium channel blockers. Most, if not all, of these patients require therapy with a lipid lowering agent as well. The National Cholesterol Education Program (NCEP) recognizes patients with existing coronary artery disease as a special class requiring aggressive management of raised LDL-C.
  • Amlodipine helps to prevent myocardial ischemia in patients with exertional angina pectoris by reducing Total Peripheral Resistance, or afterload, which reduces the rate pressure product and thus myocardial oxygen demand at any particular level of exercise. In patients with vasospastic angina pectoris, amlodipine has been demonstrated to block constriction and thus restore myocardial oxygen supply. Further, amlodipine has been shown to increase myocardial oxygen supply by dilating the coronary arteries.
  • Hypertension frequently coexists with hyperlipidemia and both are considered to be major risk factors for developing cardiac disease ultimately resulting in adverse cardiac events. This clustering of risk factors is potentially due to a common mechanism. Further, patient compliance with the management of hypertension is generally better than patient compliance with hyperlipidemia. It would therefore be advantageous for patients to have a single therapy which treats both of these conditions.
  • Coronary heart disease is a multifactorial disease in which the incidence and severity are affected by the lipid profile, the presence of diabetes and the sex of the subject. Incidence is also affected by smoking and left ventricular hypertrophy which is secondary to hypertension. To meaningfully reduce the risk of coronary heart disease, it is important to manage the entire risk spectrum. For example, hypertension intervention trials have failed to demonstrate full normalization in cardiovascular mortality due to coronary heart disease. Treatment with cholesterol synthesis inhibitors in patients with and without coronary artery disease reduces the risk of cardiovascular morbidity and mortality.
  • The Framingham Heart Study, an ongoing prospective study of adult men and women, has shown that certain risk factors can be used to predict the development of coronary heart disease. (see Wilson et al., Am. J. Cardiol. 1987, 59(14):91G-94G). These factors include age, gender, total cholesterol level, high density lipoprotein (HDL) level, systolic blood pressure, cigarette smoking, glucose intolerance and cardiac enlargement (left ventricular hypertrophy on electrocardiogram, echocardiogram or enlarged heart on chest X-ray). Calculators and computers can easily be programmed using a multivariate logistic function that allows calculation of the conditional probability of cardiovascular events. These determinations, based on experience with 5,209 men and women participating in the Framingham study, estimate coronary artery disease risk over variable periods of follow-up. Modeled incidence rates range from less than 1% to greater than 80% over an arbitrarily selected six year interval. However, these rates are typically less than 10% and rarely exceed 45% in men and 25% in women.
  • Kramsch et al., Journal of Human Hypertension (1995) (Suppl. 1), 53-59 disclose the use of calcium channel blockers, including amlodipine, to treat atherosclerosis. That reference further suggests that atherosclerosis can be treated with a combination of amlodipine and a lipid lowering agent. Human trials have shown that calcium channel blockers have beneficial effects in the treatment of early atherosclerotic lesions. (see, e.g., Lichtlen, P. R. et al., Retardation of angiographic progression o coronary artery disease by nifedipine, Lancet, 1990, 335, 1109-13; and Waters, D. et al., A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis, Circulation, 1990, 82, 1940-53.) U.S. Pat. No. 4,681,893 discloses that certain statins, including atorvastatin, are hypolipidemic agents and as such are useful in treating atherosclerosis. Jukema et al., Circulation, 1995 (Suppl. 1), 1-197, disclose that there is evidence that calcium channel blockers act synergistically in combination with lipid lowering agents (e.g., HMG-CoA reductase inhibitors), specifically pravastatin. Orekhov et al., Cardiovascular Drugs and Therapy, 1997, 11, 350 disclose the use of amlodipine in combination with lovastatin for the treatment of atherosclerosis.
  • SUMMARY OF THE INVENTION
  • This invention is directed to a pharmaceutical composition, hereinafter termed “Composition A”, comprising:
      • a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof;
      • b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and
      • c. a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a pharmaceutical composition, hereinafter termed “Composition AA”, of Composition A comprising amlodipine besylate.
  • This invention is more particularly directed to a pharmaceutical composition, hereinafter termed “Composition AB”, of Composition AA comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition B”, for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition BA”, of Composition B wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition BB”, of Composition BA comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition C”, for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the sum of the antihypertensive and hypolipidemic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition CA”, of Composition C comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition CB”, of Composition CA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition D”, for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition DA”, of Composition D comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition DB”, of Composition DA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition E”, for use with a second pharmaceutical composition for achieving a antihypertensive effect and a hypolipidemic effect in a mammal suffering from hypertension and hyperlipidemia, which effects are greater than the antihypertensive and hypolipidemic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition EA”, of Composition E wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition EB” of Composition EA comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition F”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition FA”, of Composition F comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition FB”, of Composition FA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition G”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the sum of the antiangina effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition GA”, of Composition G wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition GB”, of Composition G comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition H”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent. acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition HA”, of Composition H comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition HB”, of Composition HA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition J”, for use with a second pharmaceutical composition for achieving an antianginal effect in a mammal suffering from angina pectoris, which effect is greater than the antianginal effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition JA”, of Composition J wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition JB”, of Composition JA comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition K”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition KA”, of Composition K wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition KB”, of Composition KA comprising the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a composition, hereinafter termed “Composition KC”, of Composition KB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition KC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition KB wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • This invention is more particularly directed to a composition, hereinafter termed “Composition KD”, of Composition KB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition KD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition L”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the sum of the antiatherosclerotic effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition LA”, of Composition L comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition LB”, of Composition LA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a composition, hereinafter termed “LC”, of Composition LB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition LC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • This invention is more particularly directed to a composition, hereinafter termed “Composition LD”, of Composition LB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition LD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition M”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition MA”, of Composition M comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition MB”, of Composition MA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a composition, hereinafter termed “Composition MC”, of Composition MB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition MC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • This invention is more particularly directed to a composition, hereinafter termed “Composition MD”, of Composition MB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition MD wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition N”, for use with a second pharmaceutical composition for achieving an antiatherosclerotic effect in a mammal, which effect is greater than the antiatherosclerotic effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition NA”, of Composition N wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition, hereinafter termed “Composition NB”, of Composition NA comprising the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a composition, hereinafter termed “Composition NC”, of Composition NB wherein said antiatherosclerotic effect is manifested by a slowing of the progression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is also particularly directed to a composition of Composition NC wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • This invention is more particularly directed to a composition, hereinafter termed “Composition ND”, of Composition NB wherein said antiatherosclerotic effect is manifested by a regression of atherosclerotic plaques.
  • This invention is still more particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is also particularly directed to a composition of Composition ND wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition P”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition PA”, of Composition P comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition PA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition Q”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the sum of the cardiac risk management effects achieved by administering said first and second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition QA”, of Composition Q wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition QA comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition R”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition RA”, of Composition R comprising amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition RA wherein said second pharmaceutical composition comprises the hemicalcium salt of atorvastatin.
  • This invention is also directed to a first pharmaceutical composition, hereinafter termed “Composition S”, for use with a second pharmaceutical composition for managing cardiac risk in a mammal at risk of suffering an adverse cardiac event, which effect is greater than the cardiac risk management effects achieved by administering said first or second pharmaceutical compositions separately and which second pharmaceutical composition comprises an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent, said first pharmaceutical composition comprising an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a first pharmaceutical composition, hereinafter termed “Composition SA”, of Composition S wherein said second pharmaceutical composition comprises amlodipine besylate.
  • This invention is more particularly directed to a first pharmaceutical composition of Composition S comprising the hemicalcium salt of atorvastatin.
  • This invention is also directed to a kit, hereinafter termed “Kit A”, for achieving a therapeutic effect in a mammal comprising:
      • a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;
      • b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and
      • c. container means for containing said first and second dosage forms.
  • This invention is particularly directed to a kit, hereinafter termed “Kit AA”, of Kit A comprising amlodipine besylate.
  • This invention is more particularly directed to a kit, hereinafter termed “Kit AB”, of Kit AA comprising the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a kit, hereinafter termed “Kit AC”, of Kit AB wherein said therapeutic effect is treatment of hypertension and hyperlipidemia.
  • This invention is still more particularly directed to a kit, hereinafter termed “Kit AD”, of Kit AB wherein said therapeutic effect is treatment of angina pectoris.
  • This invention is also particularly directed to a kit, hereinafter termed “Kit AE”, of Kit AB wherein said therapeutic effect is management of cardiac risk.
  • This invention is also particularly directed to a kit, hereinafter termed “Kit AF”, of Kit AB wherein said therapeutic effect is treatment of atherosclerosis.
  • This invention is still more particularly directed to a kit, hereinafter termed “Kit AG”, of Kit AF wherein said treatment of atherosclerosis slows the progression of atherosclerotic plaques.
  • This invention is further directed to a kit, hereinafter termed “Kit AH”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in coronary arteries.
  • This invention is still further directed to a kit, hereinafter termed “Kit AJ”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in carotid arteries.
  • This invention is still further directed to a kit, hereinafter termed “Kit AK”, of Kit AG wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.
  • This invention is still further directed to a kit, hereinafter termed “Kit AL”, of Kit AF wherein said treatment of atherosclerosis causes the regression of atherosclerotic plaques.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in coronary arteries.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in carotid arteries.
  • This invention is still further directed to a kit of Kit AL wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.
  • This invention is also directed to a method, hereinafter termed “Method A”, for treating a mammal in need of therapeutic treatment comprising administering to said mammal
      • (a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
      • (b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof;
        wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable carrier or diluent.
  • This invention is particularly directed to a method, hereinafter Method B, of Method A comprising amlodipine besylate.
  • This invention is more particularly directed to a method, hereinafter termed “Method C”, of Method B comprising the hemicalcium salt of atorvastatin.
  • This invention is still more particularly directed to a method, hereinafter termed “Method D”, of Method A wherein said first compound and said second compound are administered simultaneously.
  • This invention is still more particularly directed to a method, hereinafter termed “Method E”, of Method A wherein said first compound and said second compound are administered sequentially in either order.
  • This invention is also particularly directed to a method, hereinafter termed “Method F”, of Method C wherein said first compound and said second compound are administered simultaneously.
  • This invention is further directed to a method, hereinafter termed “Method G”, of Method C wherein said first compound and said second compound are administered sequentially in either order.
  • This invention is still further directed to a method of Method A wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is still further directed to a method of Method F wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is still further directed to a method of Method G wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antianginal treatment.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises cardiac risk management.
  • This invention is further directed to a method of Method A wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • This invention is further directed to a method of Method F wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • This invention is further directed to a method of Method G wherein said therapeutic treatment comprises antiatherosclerotic treatment.
  • Amlodipine is a racemic compound due to the symmetry at position 4 of the dihydropyridine ring. The R and S enantiomers may be prepared as described by Arrowsmith et al., J. Med. Chem., 1986, 29, 1696. The calcium channel blocking activity of amlodipine is substantially confined to the S(−) isomer and to the racemic mixture containing the R(+) and S(−) forms. (see International Patent Application Number PCT/EP94/02697). The R(+) isomer has little or no calcium channel blocking activity. However, the R(+) isomer is a potent inhibitor of smooth muscle cell migration. Thus, the R(+) isomer is useful in the treatment or prevention of atherosclerosis. (see International Patent Application Number PCT/EP95/00847). Based on the above, a skilled person could choose the R(+) isomer, the S(−) isomer or the racemic mixture of the R(+) isomer and the S(−) isomer for use in the combination of this invention.
  • Where used herein, the term “cardiac risk” means the likelihood that a subject will suffer a future adverse cardiac event such as, e.g., myocardial infarction, cardiac arrest, cardiac failure, cardiac ischaemia. Cardiac risk is calculated using the Framingham Risk Equation as set forth above. The term “cardiac risk management” means that the risk of future adverse cardiac events is substantially reduced.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The pharmaceutical compositions of this invention comprise amlodipine or a pharmaceutically acceptable acid addition salt thereof and/or atorvastatin or a pharmaceutically acceptable salt thereof.
  • Amlodipine may readily be prepared as described in U.S. Pat. No. 4,572,909 which is incorporated herein by reference. Amlodipine besylate, which is currently sold as Norvasc®, may be prepared as described in U.S. Pat. No. 4,879,303, which is incorporated herein by reference. Amlodipine and amlodipine besylate are potent and long lasting calcium channel blockers.
  • The expression “pharmaceutically-acceptable acid addition salts” is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, besylate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • Other acid addition salts of amlodipine may be prepared by reacting the free base form of amlodipine with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate) or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base of amlodipine and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • Atorvastatin may readily be prepared as described in U.S. Pat. No. 4,681,892, which is incorporated herein by reference. The hemicalcium salt of atorvastatin, which is currently sold as Lipitor®, may readily be prepared as described in U.S. Pat. No. 5,273,995, which is incorporated herein by reference.
  • The expression “pharmaceutically acceptable salts” includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The expression “pharmaceutically-acceptable cationic salts” is intended to define but is not limited to such salts as the alkali metal salts, (e.g. sodium and potassium), alkaline earth metal salts (e.g. calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N□-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression “pharmaceutically-acceptable acid addition salts” is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
  • Other pharmaceutically-acceptable cationic salts of atorvastatin may be readily prepared by reacting the free acid form of atorvastatin with an appropriate base, usually one equivalent, in a co-solvent. Typical bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine. The salt is isolated by concentration to dryness or by addition of a non-solvent. In many cases, salts are preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (e.g., sodium or potassium ethylhexanoate, magnesium oleate) and employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates. The salts may also be isolated by concentrating the reaction solution and/or by adding a non-solvent.
  • The acid addition salts of atorvastatin may be readily prepared by reacting the free base form of atorvastatin with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate) or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base and the acid are usually combined in a co-solvent from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.
  • In addition, amlodipine, pharmaceutically acceptable acid addition salts thereof, atorvastatin and pharmaceutically acceptable salts thereof may occur as hydrates or solvates. Said hydrates and solvates are also within the scope of the invention.
  • The pharmaceutical combinations and methods of this invention are all adapted to therapeutic use as agents in the treatment of atherosclerosis, angina pectoris, and a condition characterized by the presence of both hypertension and hyperlipidemia in mammals, particularly humans. Further, since these diseases and conditions are closely related to the development of cardiac disease and adverse cardiac conditions, these combinations and methods, by virtue of their action as antiatherosclerotics, antianginals, antihypertensives and antihyperlipidemics, are useful in the management of cardiac risk.
  • The utility of the compounds of the present invention as medical agents in the treatment of atherosclerosis in mammals (e.g. humans) is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:
  • Effect of Amlodipine and Atorvastatin, Alone and in Combination, on the Treatment of Atherosclerosis
  • This study is a prospective randomized evaluation of the effect of a combination of amlodipine and atorvastatin on the progression/regression of coronary and carotid artery disease. The study is used to show that a combination of amlodipine and atorvastatin is effective in slowing or arresting the progression or causing regression of existing coronary artery disease (CAD) as evidenced by changes in coronary angiography or carotid ultrasound, in subjects with established disease.
  • This study is an angiographic documentation of coronary artery disease carried out as a double-blind, placebo-controlled trial of a minimum of about 500 subjects and preferably of about 780 to about 1200 subjects. It is especially preferred to study about 1200 subjects in this study. Subjects are admitted into the study after satisfying certain entry criteria set forth below.
  • Entry criteria: Subjects accepted for entry into this trial must satisfy certain criteria. Thus the subject must be an adult, either male or female, aged 18-80 years of age in whom coronary angiography is clinically indicated. Subjects will have angiographic presence of a significant focal lesion such as 30% to 50% on subsequent evaluation by quantitative coronary angiography (QCA) in a minimum of one segment (non-PTCA, non-bypassed or non-MI vessel) that is judged not likely to require intervention over the next 3 years. It is required that the segments undergoing analysis have not been interfered with. Since percutaneous transluminal cardiac angioplasty (PTCA) interferes with segments by the insertion of a balloon catheter, non-PTCA segments are required for analysis. It is also required that the segments to be analyzed have not suffered a thrombotic event, such as a myocardial infarct (MI). Thus the requirement for non-MI vessels. Segments that will be analyzed include: left main, proximal, mid and distal left anterior descending, first and second diagonal branch, proximal and distal left circumflex, first or largest space obtuse marginal, proximal, mid and distal right coronary artery. Subjects will have an ejection fraction of greater than 30% determined by catheterization or radionuclide ventriculography or ECHO cardiogram at the time of the qualifying angiogram or within the previous three months of the acceptance of the qualifying angiogram provided no intervening event such as a thrombotic event or procedure such as PTCA has occurred.
  • Generally, due to the number of patients and the physical limitations of any one facility, the study is carried out at multiple sites. At entry into the study, subjects undergo quantitative coronary angiography as well as B-mode carotid artery ultrasonography and assessment of carotid arterial compliance at designated testing centers. This establishes baselines for each subject. Once admitted into the test, subjects are randomized to receive amlodipine besylate (10 mgs) and placebo or atorvastatin calcium (80 mgs) and placebo or amlodipine besylate (10 mgs) and atorvastatin calcium (80 mgs). All doses set forth in this protocol are per day doses. The amount of amlodipine besylate may be varied as required. Generally, a subject will start out taking 10 mg and the amount will be titrated down to as little as 5 mg as determined by the clinical physician. The amount of atorvastatin calcium will similarly be titrated down from 80 mg if it is determined by the physician to be in the best interests of the subject. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • The subjects are monitored for a one to three year period, generally three years being preferred. B-mode carotid ultrasound assessment of carotid artery atherosclerosis and compliance are performed at regular intervals throughout the study.
  • Generally, six month intervals are suitable. Typically this assessment is performed using B-mode ultrasound equipment. However, a person skilled in the art may use other methods of performing this assessment. Coronary angiography is performed at the conclusion of the one to three year treatment period. The baseline and post-treatment angiograms and the intervening carotid artery B-mode ultrasonograms are evaluated for new lesions or progression of existing atherosclerotic lesions. Arterial compliance measurements are assessed for changes from baseline and over the 6-month evaluation periods.
  • The primary objective of this study is to show that the combination of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof reduces the progression of atherosclerotic lesions as measured by quantitative coronary angiography (QCA) in subjects with clinical coronary artery disease. QCA measures the opening in the lumen of the arteries measured.
  • The primary endpoint of the study is the change in the average mean segment diameter of the coronary artery tree. Thus, the diameter of an arterial segment is measured at various portions along the length of that segment. The average diameter of that segment is then determined. After the average segment diameter of many segments has been determined, the average of all segment averages is determined to arrive at the average mean segment diameter. The mean segment diameter of subjects taking atorvastatin or pharmaceutically acceptable salts thereof and amlodipine or pharmaceutically acceptable acid addition salts thereof will decline more slowly, will be halted completely, or there will be an increase in the mean segment diameter. These results represent slowed progression of atherosclerosis, halted progression of atherosclerosis and regression of atherosclerosis, respectively.
  • The secondary objective of this study is to show that the combination of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically salt thereof reduces the rate of progression of atherosclerosis in the carotid arteries as measured by the slope of the maximum intimal-medial thickness measurements averaged over 12 separate wall segments (Mean Max) as a function of time, more than does amlodipine or a pharmaceutically acceptable acid addition salt thereof or atorvastatin or a pharmaceutically acceptable salt thereof alone. The intimal-medial thickness of subjects taking atorvastatin or a pharmaceutically acceptable salt thereof and amlodipine or a pharmaceutically acceptable acid addition salt thereof will increase more slowly, will cease to increase or will decrease. These results represent slowed progression of atherosclerosis, halted progression of atherosclerosis and regression of atherosclerosis, respectively.
  • The utility of the compounds of the present invention as medical agents in the treatment of angina pectoris in mammals (e.g., humans) is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:
  • Effect of Amlodipine and Atorvastatin, Alone and in Combination, on the Treatment of Angina
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in the treatment of symptomatic angina.
  • Entry criteria: Subjects are males or females between 18 and 80 years of age with a history of typical chest pain associated with one of the following objective evidences of cardiac ischemia: (1) stress test segment elevation of about one millimeter or more from the ECG; (2) positive treadmill stress test; (3) new wall motion abnormality on ultrasound; or (4) coronary angiogram with a significant qualifying stenosis. Generally a stenosis of about 30-50% is considered to be significant.
  • Each subject is evaluated for about ten to thirty-two weeks. At least ten weeks are generally required to complete the study. Sufficient subjects are used in this screen to ensure that about 200 to 800 subjects and preferably about 400 subject are evaluated to complete the study. Subjects are screened for compliance with the entry criteria, set forth below, during a four week run in phase. After the screening criteria are met, subjects are washed out from their current anti-anginal medication and stabilized on a long acting nitrate such as, for example, nitroglycerin, isosorbide-5-mononitrate or isosorbide dinitrate. The term “washed out”, when used in connection with this screen, means the withdrawal of current anti-anginal medication so that substantially all of said medication is eliminated from the body of the subject. A period of eight weeks is preferably allowed for both the wash out period and for the establishment of the subject on stable doses of said nitrate. Subjects having one or two attacks of angina per week while on stable doses of long acting nitrate are generally permitted to skip the wash out phase. After subjects are stabilized on nitrates, the subjects enter the randomization phase provided the subjects continue to have either one or two angina attacks per week. In the randomization phase, the subjects are randomly placed into one of the four arms of the study set forth below. After completing the wash out phase, subjects in compliance with the entry criteria undergo twenty four hour ambulatory electrocardiogram (ECG) such as Holter monitoring, exercise stress testing such as a treadmill and evaluation of myocardial perfusion using PET (photon emission tomography) scanning to establish a baseline for each subject. When conducting a stress test, the speed of the treadmill and the gradient of the treadmill can be controlled by a technician. The speed of the treadmill and the angle of the gradient are generally increased during the test. The time intervals between each speed and gradient increase is generally determined using a modified Bruce Protocol.
  • After the baseline investigations have been completed, subjects are initiated on one of the following four arms of the study: (1) placebo; (2) atorvastatin calcium (about 2.5 mg to about 160 mg); (3) amlodipine besylate (about 2.5 mg to about 20 mg); or (4) a combination of the above doses of amlodipine besylate and atorvastatin calcium together. The subjects are then monitored for two to twenty four weeks. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • After the monitoring period has ended, subjects will undergo the following investigations: (1) twenty four hour ambulatory ECG, such as Holter monitoring; (2) exercise stress testing (e.g. treadmill using said modified Bruce Protocol); and (3) evaluation of myocardial perfusion using PET scanning. Patients keep a diary of painful ischemic events and nitroglycerine consumption. It is generally desirable to have an accurate record of the number of anginal attacks suffered by the patient during the duration of the test. Since a patient generally takes nitroglycerin to ease the pain of an anginal attack, the number of times that the patient administers nitroglycerine provides a reasonably accurate record of the number of anginal attacks.
  • To demonstrate the effectiveness of the drug combination of this invention, and to determine the dosage amounts of the drug combination of this invention, the person conducting the test will evaluate the subject using the tests described. Successful treatment will yield fewer instances of ischemic events as detected by ECG, will allow the subject to exercise longer or at a higher intensity level on the treadmill, or to exercise without pain on the treadmill, or will yield better perfusion or fewer perfusion defects on photoemission tomography (PET).
  • The utility of the compounds of the present invention as medical agents in the treatment of hypertension and hyperlipidemia in mammals (e.g., humans) suffering from a combination of hypertension and hyperlipidemia is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:
  • Effect of Amlodipine and Atorvastatin, Alone and in Combination, on the Treatment of Subjects Having Both Hypertension and Hyperlipidemia
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination in controlling both hypertension and hyperlipidemia in subjects who have mild, moderate, or severe hypertension and hyperlipidemia.
  • Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are used in this screen to ensure that about 400 to 800 subjects are evaluated to complete the study.
  • Entry criteria: Subjects are male or female adults between 18 and 80 years of age having both hyperlipidemia and hypertension. The presence of hyperlipidemia is evidenced by evaluation of the low density lipoprotein (LDL) level of the subject relative to certain positive risk factors. If the subject has no coronary heart disease (CHD) and has less than two positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 190. If the subject has no CHD and has two or more positive risk factors, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 160. If the subject has CHD, then the subject is considered to have hyperlipidemia if the LDL of the subject is greater than or equal to 130.
  • Positive risk factors include (1) male over 45, (2) female over 55 wherein said female is not undergoing hormone replacement therapy (HRT), (3) family history of premature cardiovascular disease, (4) the subject is a current smoker, (5) the subject has diabetes, (6) an HDL of less than 45, and (7) the subject has hypertension. An HDL of greater than 60 is considered a negative risk factor and will offset one of the above mentioned positive risk factors.
  • The presence of hypertension is evidenced by a sitting diastolic blood pressure (BP) of greater than 90 or sitting systolic BP of greater than 140. All blood pressures are generally determined as the average of three measurements taken five minutes apart.
  • Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, subjects are washed out from their current antihypertensive and lipid lowering medication and are placed on the NCEP ATP II Step 1 diet. The NCEP ATP II (adult treatment panel, 2nd revision) Step 1 diet sets forth the amount of saturated and unsaturated fat which can be consumed as a proportion of the total caloric intake. The term “washed out” where used in connection with this screen, means the withdrawal of current antihypertensive and lipid lowering medication so that substantially all of said medication is eliminated from the body of the subject. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP Step 1 diet. After the four week wash out and diet stabilization period, subjects undergo the following baseline investigations: (1) blood pressure and (2) fasting lipid screen. The fasting lipid screen determines baseline lipid levels in the fasting state of a subject. Generally, the subject abstains from food for twelve hours, at which time lipid levels are measured.
  • After the baseline investigations are performed subjects are started on one of the following: (1) a fixed dose of amlodipine besylate, generally about 2.5 to 10 mg; (2) a fixed dose of atorvastatin calcium, generally about 10 to 80 mg; or (3) a combination of the above doses of amlodipine besylate and atorvastatin calcium together. Subjects remain on these doses for a minimum of six weeks, and generally for no more than eight weeks. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved. The subjects return to the testing center at the conclusion of the six to eight weeks so that the baseline evaluations can be repeated. The blood pressure of the subject at the conclusion of the study is compared with the blood pressure of the subject upon entry. The lipid screen measures the total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apoB, VLDL (very low density lipoprotein) and other components of the lipid profile of the subject. Improvements in the values obtained after treatment relative to pretreatment values indicate the utility of the drug combination.
  • The utility of the compounds of the present invention as medical agents in the management of cardiac risk in mammals (e.g., humans) at risk for an adverse cardiac event is demonstrated by the activity of the compounds of this invention in conventional assays and the clinical protocol described below:
  • Effects of Amlodipine and Atorvastatin, Alone and in Combination, on Subjects at Risk of Future Cardiovascular Events
  • This study is a double blind, parallel arm, randomized study to show the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof given in combination are effective in reducing the overall calculated risk of future events in subjects who are at risk for having future cardiovascular events. This risk is calculated by using the Framingham Risk Equation. A subject is considered to be at risk of having a future cardiovascular event if that subject is more than one standard deviation above the mean as calculated by the Framingham Risk Equation. The study is used to evaluate the efficacy of a fixed combination of amlodipine and atorvastatin in controlling cardiovascular risk by controlling both hypertension and hyperlipidemia in patients who have both mild to moderate hypertension and hyperlipidemia.
  • Each subject is evaluated for 10 to 20 weeks and preferably for 14 weeks. Sufficient subjects are recruited to ensure that about 400 to 800 subjects are evaluated to complete the study.
  • Entry criteria: Subjects included in the study are male or female adult subjects between 18 and 80 years of age with a baseline five year risk which risk is above the median for said subject's age and sex, as defined by the Framingham Heart Study, which is an ongoing prospective study of adult men and women showing that certain risk factors can be used to predict the development of coronary heart disease. The age, sex, systolic and diastolic blood pressure, smoking habit, presence or absence of carbohydrate intolerance, presence or absence of left ventricular hypertrophy, serum cholesterol and high density lipoprotein (HDL) of more than one standard deviation above the norm for the Framingham Population are all evaluated in determining whether a patient is at risk for adverse cardiac event. The values for the risk factors are inserted into the Framingham Risk equation and calculated to determine whether a subject is at risk for a future cardiovascular event.
  • Subjects are screened for compliance with the entry criteria set forth above. After all screening criteria are met, patients are washed out from their current antihypertensive and lipid lowering medication and any other medication which will impact the results of the screen. The patients are then placed on the NCEP ATP II Step 1 diet, as described above. Newly diagnosed subjects generally remain untreated until the test begins. These subjects are also placed on the NCEP ATP II Step 1 diet. After the four week wash out and diet stabilization period, subjects undergo the following baseline investigations: (1) blood pressure; (2) fasting; (3) lipid screen; (4) glucose tolerance test; (5) ECG; and (6) cardiac ultrasound. These tests are carried out using standard procedures well known to persons skilled in the art. The ECG and the cardiac ultrasound are generally used to measure the presence or absence of left ventricular hypertrophy.
  • After the baseline investigations are performed patients will be started on one of the following: (1) a fixed dose of amlodipine (about 2.5 to 10 mg); (2) a fixed dose of atorvastatin (about 10 to 80 mg); or (3) the combination of the above doses of amlodipine and atorvastatin. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate or the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of atorvastatin calcium and amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved. Patients are kept on these doses and are asked to return in six to eight weeks so that the baseline evaluations can be repeated. At this time the new values are entered into the Framingham Risk equation to determine whether the subject has a lower, greater or no change in the risk of future cardiovascular event.
  • The above assays demonstrating the effectiveness of amlodipine or pharmaceutically acceptable acid addition salts thereof and atorvastatin or pharmaceutically acceptable salts thereof in the treatment of angina pectoris, atherosclerosis, hypertension and hyperlipidemia together, and the management of cardiac risk, also provide a means whereby the activities of the compounds of this invention can be compared between themselves and with the activities of other known compounds. The results of these comparisons are useful for determining dosage levels in mammals, including humans, for the treatment of such diseases.
  • The following dosage amounts and other dosage amounts set forth elsewhere in the specification and in the appendant claims are for an average human subject having a weight of about 65 kg to about 70 kg. The skilled practitioner will readily be able to determine the dosage amount required for a subject whose weight falls outside the 65 kg to 70 kg range, based upon the medical history of the subject and the presence of diseases, e.g., diabetes, in the subject. All doses set forth herein, and in the appendant claims, are daily doses.
  • In general, in accordance with this invention, amlodipine besylate is generally administered in a dosage of about 2.5 mg to about 20 mg. Preferably, amlodipine besylate is administered in a dosage of about 5 mg to about 10 mg. It will be recognized by a skilled person that the free base form or other salt forms of amlodipine besylate may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of amlodipine besylate is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • In general, in accordance with this invention, atorvastatin is administered in a dosage of about 2.5 mg to about 160 mg. Preferably, atorvastatin is administered in a dosage of about 10 mg to about 80 mg. It will be recognized by a skilled person that the free base form or other salt forms of atorvastatin calcium may be used in this invention. Calculation of the dosage amount for these other forms of or the free base form or other salt forms of atorvastatin calcium is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
  • The compounds of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the compounds of this invention together with a pharmaceutically acceptable carrier or diluent. Thus, the compounds of this invention can be administered either individually or together in any conventional oral, parenteral or transdermal dosage form.
  • For oral administration a pharmaceutical composition can take the form of solutions, suspensions, tablets, pills, capsules, powders, and the like. Tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate are employed along with various disintegrants such as starch and preferably potato or tapioca starch and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type are also employed as fillers in soft and hard-filled gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the compounds of this invention can be combined with various sweetening agents, flavoring agents, coloring agents, emulsifying agents and/or suspending agents, as well as such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • The combination of this invention may also be administered in a controlled release formulation such as a slow release or a fast release formulation. Such controlled release dosage formulations of the combination of this invention may be prepared using methods well known to those skilled in the art. The method of preferred administration will be determined by the attendant physician or other person skilled in the art after an evaluation of the subject's condition and requirements. The generally preferred formulation of amlodipine is Norvasc®. The generally preferred formulation of atorvastatin is Lipitor®.
  • For purposes of parenteral administration, solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts. Such aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.
  • Methods of preparing various pharmaceutical compositions with a certain amount of active ingredient are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).
  • Pharmaceutical compositions according to the invention may contain 0.1%-95% of the compound(s) of this invention, preferably 1%-70%. In any event, the composition or formulation to be administered will contain a quantity of a compound(s) according to the invention in an amount effective to treat the condition or disease of the subject being treated.
  • Since the present invention relates to the treatment of diseases and conditions with a combination of active ingredients which may be administered separately, the invention also relates to combining separate pharmaceutical compositions in kit form. The kit includes two separate pharmaceutical compositions: amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof. The kit includes container means for containing the separate compositions such as a divided bottle or a divided foil packet, however, the separate compositions may also be contained within a single, undivided container. Typically the kit includes directions for the administration of the separate components. The kit form is particularly advantageous when the separate components are preferably administered in different dosage forms (e.g., oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician.
  • It should be understood that the invention is not limited to the particular embodiments described herein, but that various changes and modifications may be made without departing from the spirit and scope of this novel concept as defined by the following claims.

Claims (54)

1-117. (canceled)
118. A method for treating a mammal suffering from angina comprising administering to said mammal
(a) an amount of a first therapeutic agent, said first agent being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
(b) an amount of a second therapeutic agent, said second agent being atorvastatin or a pharmaceutically acceptable salt thereof;
wherein said first agent and second agent are administered together in a single pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent.
119. The method of claim 118 wherein said first agent comprises amlodipine besylate.
120. The method of claim 118 wherein said second agent comprises hemicalcium salt of atorvastatin.
121. The method of claim 119 wherein said second agent comprises hemicalcium salt of atorvastatin.
122. The method of claim 118 wherein said first agent is present in an amount of from about 2.5 mg to about 20 mg and said second agent is present in an amount of from about 2.5 mg to about 160 mg.
123. The method of claim 121, wherein said hemicalcium salt of atorvastatin is present in an amount of from about 2.5 mg to about 160 mg and said amlodipine besylate is present in an amount of from about 2.5 mg to about 20 mg.
124. The method of claim 121, wherein said hemicalcium salt of atorvastatin is present in an amount of from about 10 mg to about 80 mg and said amlodipine besylate is present in an amount of from about 5 mg to about 10 mg.
125. The method of claim 118 wherein said mammal is a human who also suffers from hypertension.
126. The method of claim 118 wherein said mammal is a human who also suffers from hyperlipidemia.
127. The method of claim 118 wherein said mammal is a human who also suffers from combined hypertension and hyperlipidemia.
128. The method of claim 118 wherein said mammal is a human who also suffers from atherosclerosis.
129. The method of claim 123 wherein said mammal is a human who also suffers from hypertension.
130. The method of claim 123 wherein said mammal is a human who also suffers from hyperlipidemia.
131. The method of claim 123 wherein said mammal is a human who also suffers from combined hypertension and hyperlipidemia.
132. The method of claim 123 wherein said mammal is a human who also suffers from atherosclerosis.
133. The method of claim 131 wherein said hemicalcium salt of atorvastatin is present in an amount of from about 10 mg to about 80 mg and said amlodipine besylate is present in an amount of from about 5 mg to about 10 mg.
134. The method of claim 118 wherein the pharmaceutically acceptable acid addition salt of amlodipine is not amlodipine besylate, and is present in an amount equivalent to from 2.5 mg to 20 mg of amlodipine besylate.
135. The method of claim 134 wherein said first agent comprises amlodipine mesylate.
136. The method of claim 134 wherein said first agent comprises amlodipine maleate.
137. The method of claim 134 wherein said first agent comprises amlodipine tosylate.
138. The method of claim 118 wherein said pharmaceutical composition is administered orally in the form of a solution, suspension, tablet, pill, capsule or powder.
139. The method of claim 121 comprising 5 mg of amlodipine besylate and 10 mg of atorvastatin hemicalcium.
140. The method of claim 121 comprising 5 mg of amlodipine besylate and 80 mg of atorvastatin hemicalcium.
141. The method of claim 121 comprising 10 mg of amlodipine besylate and 10 mg of atorvastatin hemicalcium.
142. The method of claim 121 comprising 10 mg of amlodipine besylate and 80 mg of atorvastatin hemicalcium.
143. A method of treating a human diagnosed as suffering from angina, and who would benefit from the administration of prescribed therapeutic agents, the method comprising administering to said human
(a) an amount of a first therapeutic agent, said first agent being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
(b) an amount of a second therapeutic agent, said second agent being atorvastatin or a pharmaceutically acceptable salt thereof;
wherein said first agent and second agent are administered together in a single pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent.
144. The method of claim 143 wherein said first agent comprises amlodipine besylate.
145. The method of claim 143 wherein said second agent comprises hemicalcium salt of atorvastatin.
146. The method of claim 144 wherein said second agent comprises hemicalcium salt of atorvastatin.
147. The method of claim 146, wherein said hemicalcium salt of atorvastatin is present in an amount of from about 2.5 mg to about 160 mg and said amlodipine besylate is present in an amount of from about 2.5 mg to about 20 mg.
148. The method of claim 146, wherein said hemicalcium salt of atorvastatin is present in an amount of from about 10 mg to about 80 mg and said amlodipine besylate is present in an amount of from about 5 mg to about 10 mg.
149. The method of claim 143 wherein the pharmaceutically acceptable acid addition salt of amlodipine is not amlodipine besylate, and is present in an amount equivalent to from 2.5 mg to 20 mg of amlodipine besylate.
150. The method of claim 143 wherein said mammal is a human who also suffers from hypertension.
151. The method of claim 143 wherein said mammal is a human who also suffers from hyperlipidemia.
152. The method of claim 143 wherein said mammal is a human who also suffers from combined hypertension and hyperlipidemia.
153. The method of claim 143 wherein said mammal is a human who also suffers from atherosclerosis.
154. A method for treating angina in a human who has been examined for angina by a medical practitioner and diagnosed in need of therapy for said angina treatment by the joint administration of a first therapeutic agent and a second therapeutic agent, which comprises administering to said human
(a) an amount of said first therapeutic agent, said first agent being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and
(b) an amount of said second therapeutic agent, said second agent being atorvastatin or a pharmaceutically acceptable salt thereof;
wherein said first agent and second agent are administered together in a single pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent.
155. The method of claim 154 wherein said first agent comprises amlodipine besylate.
156. The method of claim 154 wherein said second agent comprises hemicalcium salt of atorvastatin.
157. The method of claim 155 wherein said second agent comprises hemicalcium salt of atorvastatin.
158. The method of claim 154 wherein said first agent is present in an amount of from about 2.5 mg to about 20 mg and said second agent is present in an amount of from about 2.5 mg to about 160 mg.
159. The method of claim 154 wherein said pharmaceutical composition is administered orally in the form of a solution, suspension, tablet, pill, capsule or powder.
160. The method of claim 154 wherein said first agent comprises amlodipine mesylate.
161. The method of claim 154 wherein said first agent comprises amlodipine maleate.
162. The method of claim 154 wherein said first agent comprises amlodipine tosylate.
163. The method of claim 157 comprising 5 mg of amlodipine besylate and 10 mg of atorvastatin hemicalcium.
164. The method of claim 157 comprising 5 mg of amlodipine besylate and 80 mg of atorvastatin hemicalcium.
165. The method of claim 157 comprising 10 mg of amlodipine besylate and 10 mg of atorvastatin hemicalcium.
166. The method of claim 157 comprising 10 mg of amlodipine besylate and 80 mg of atorvastatin hemicalcium.
167. The method of claim 154 wherein said human also suffers from hypertension.
168. The method of claim 154 wherein said human also suffers from hyperlipidemia.
169. The method of claim 154 wherein said human also suffers from combined hypertension and hyperlipidemia.
170. The method of claim 154 wherein said human also suffers from atherosclerosis.
US13/091,622 1997-08-29 2011-04-21 Therapeutic combination Abandoned US20110201654A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/091,622 US20110201654A1 (en) 1997-08-29 2011-04-21 Therapeutic combination
US13/445,339 US20120208854A1 (en) 1997-08-29 2012-04-12 Therapeutic combination
US13/743,897 US20130131125A1 (en) 1997-08-29 2013-01-17 Therapeutic combination
US14/049,286 US20140039017A1 (en) 1997-08-29 2013-10-09 Therapeutic combination

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5727597P 1997-08-29 1997-08-29
IBPCT/IB98/01225 1998-08-11
PCT/IB1998/001225 WO1999011259A1 (en) 1997-08-29 1998-08-11 Therapeutic combinations comprising amlodipin and atorvastatin
US09/512,914 US6455574B1 (en) 1997-08-29 2000-02-25 Therapeutic combination
US10/214,058 US20030008904A1 (en) 1997-08-29 2002-08-07 Therapeutic combination
US11/448,100 US20060223865A1 (en) 1997-08-29 2006-06-07 Therapeutic combination
US13/091,622 US20110201654A1 (en) 1997-08-29 2011-04-21 Therapeutic combination

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/448,100 Continuation US20060223865A1 (en) 1997-08-29 2006-06-07 Therapeutic combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/445,339 Continuation US20120208854A1 (en) 1997-08-29 2012-04-12 Therapeutic combination

Publications (1)

Publication Number Publication Date
US20110201654A1 true US20110201654A1 (en) 2011-08-18

Family

ID=22009597

Family Applications (11)

Application Number Title Priority Date Filing Date
US09/512,914 Expired - Lifetime US6455574B1 (en) 1997-08-29 2000-02-25 Therapeutic combination
US10/214,058 Pending US20030008904A1 (en) 1997-08-29 2002-08-07 Therapeutic combination
US10/637,781 Abandoned US20040048906A1 (en) 1997-08-29 2003-08-08 Therapeuctic combination
US11/448,100 Abandoned US20060223865A1 (en) 1997-08-29 2006-06-07 Therapeutic combination
US11/499,753 Abandoned US20060270717A1 (en) 1997-08-29 2006-08-07 Therapeutic combination
US12/427,420 Abandoned US20090297598A1 (en) 1997-08-29 2009-04-21 Therapeutic combination
US12/721,065 Abandoned US20100168187A1 (en) 1997-08-29 2010-03-10 Therapeutic combination
US13/091,622 Abandoned US20110201654A1 (en) 1997-08-29 2011-04-21 Therapeutic combination
US13/445,339 Abandoned US20120208854A1 (en) 1997-08-29 2012-04-12 Therapeutic combination
US13/743,897 Abandoned US20130131125A1 (en) 1997-08-29 2013-01-17 Therapeutic combination
US14/049,286 Abandoned US20140039017A1 (en) 1997-08-29 2013-10-09 Therapeutic combination

Family Applications Before (7)

Application Number Title Priority Date Filing Date
US09/512,914 Expired - Lifetime US6455574B1 (en) 1997-08-29 2000-02-25 Therapeutic combination
US10/214,058 Pending US20030008904A1 (en) 1997-08-29 2002-08-07 Therapeutic combination
US10/637,781 Abandoned US20040048906A1 (en) 1997-08-29 2003-08-08 Therapeuctic combination
US11/448,100 Abandoned US20060223865A1 (en) 1997-08-29 2006-06-07 Therapeutic combination
US11/499,753 Abandoned US20060270717A1 (en) 1997-08-29 2006-08-07 Therapeutic combination
US12/427,420 Abandoned US20090297598A1 (en) 1997-08-29 2009-04-21 Therapeutic combination
US12/721,065 Abandoned US20100168187A1 (en) 1997-08-29 2010-03-10 Therapeutic combination

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/445,339 Abandoned US20120208854A1 (en) 1997-08-29 2012-04-12 Therapeutic combination
US13/743,897 Abandoned US20130131125A1 (en) 1997-08-29 2013-01-17 Therapeutic combination
US14/049,286 Abandoned US20140039017A1 (en) 1997-08-29 2013-10-09 Therapeutic combination

Country Status (49)

Country Link
US (11) US6455574B1 (en)
EP (3) EP1491193B1 (en)
JP (3) JP2001514222A (en)
KR (1) KR20010023498A (en)
CN (2) CN101062035A (en)
AP (1) AP1225A (en)
AR (1) AR012269A1 (en)
AT (2) ATE332689T1 (en)
AU (1) AU755636B2 (en)
BG (1) BG64665B1 (en)
BR (1) BR9812030A (en)
CA (1) CA2301732C (en)
CO (1) CO4970694A1 (en)
CY (2) CY1105108T1 (en)
CZ (1) CZ301081B6 (en)
DE (2) DE69826683T2 (en)
DK (2) DK1491193T3 (en)
DZ (1) DZ2596A1 (en)
EA (1) EA003549B1 (en)
ES (2) ES2266961T3 (en)
GE (2) GEP20084338B (en)
GT (1) GT199800127A (en)
HN (1) HN1998000132A (en)
HR (1) HRP980473B1 (en)
HU (1) HUP0003656A3 (en)
ID (1) ID23670A (en)
IL (2) IL134303A0 (en)
IS (1) IS2029B (en)
LU (1) LU91253I2 (en)
MA (1) MA26535A1 (en)
ME (1) ME00545B (en)
MY (1) MY123993A (en)
NO (1) NO320267B1 (en)
NZ (2) NZ527158A (en)
OA (1) OA11290A (en)
PA (1) PA8457101A1 (en)
PE (1) PE107199A1 (en)
PL (1) PL192360B1 (en)
PT (2) PT1491193E (en)
RS (1) RS50485B (en)
SI (2) SI1491193T1 (en)
SK (1) SK284958B6 (en)
TN (1) TNSN98156A1 (en)
TR (1) TR200000561T2 (en)
TW (1) TW592696B (en)
UA (1) UA71897C2 (en)
UY (1) UY25157A1 (en)
WO (1) WO1999011259A1 (en)
ZA (1) ZA987844B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
UA53716C2 (en) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion
GT199800127A (en) * 1997-08-29 2000-02-01 THERAPEUTIC COMBINATIONS.
US7129265B2 (en) 1999-04-23 2006-10-31 Mason R Preston Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
PT1173172E (en) * 1999-04-23 2006-05-31 Mason R Preston SYNERGIC EFFECTS OF AMLOPIDINE AND HYDROXYLATED METABOLITE OF ATORVASTATIN
DK1180102T3 (en) 1999-05-27 2004-09-06 Pfizer Prod Inc Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (en) 1999-05-27 2001-02-02 Pfizer Prod Inc MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA
CA2314517A1 (en) 1999-07-26 2001-01-26 Gust H. Bardy System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system
EA200200240A1 (en) 1999-10-11 2002-10-31 Пфайзер Инк. 5- (2-SUBSTITUTED-5-HETEROCYCLILESULPHONYLPYRID-3-IL) -DIGIDROPYRAZOLO [4,3-d] PYRIMIDIN-7-ONE AS PHYSPHODESTERASE INHIBITORS
US6336903B1 (en) 1999-11-16 2002-01-08 Cardiac Intelligence Corp. Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof
US6835742B2 (en) 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
CA2420844A1 (en) * 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
PE20030324A1 (en) * 2001-07-31 2003-04-03 Warner Lambert Co PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
JP2007500219A (en) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション Heterocyclic compounds and uses thereof
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
JP4509118B2 (en) * 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 PHARMACEUTICAL COMPOSITION AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR STABILIZING DIHYDROPYRIDINE COMPOUNDS
MX2007006279A (en) 2004-12-15 2007-06-14 Solvay Pharm Gmbh Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors.
KR100582347B1 (en) * 2004-12-30 2006-05-22 한미약품 주식회사 Complex composition of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
WO2007111027A1 (en) 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
JP2008044870A (en) * 2006-08-11 2008-02-28 Elmed Eisai Kk Pharmaceutical composition and its production method
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
PL2120878T3 (en) 2007-02-09 2015-01-30 Alphapharm Pty Ltd A dosage form containing two active pharmaceutical ingredients in different physical forms
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
CN101742907A (en) * 2007-05-03 2010-06-16 安塞拉制药有限公司 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and spla2 inhibitor combination therapies
CN101433539A (en) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 Therapeutic compositions containing amlodipine niacin and rosuvastatin medicament
CN101433538B (en) * 2007-11-12 2012-07-25 北京瑞康医药技术有限公司 Therapeutic compositions containing amlodipine and niacin medicament
EP2161024A1 (en) 2008-09-05 2010-03-10 Universitätsklinikum Hamburg-Eppendorf Combination product for the treatment of cancer
IT1400309B1 (en) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF XANTHIN INHIBITORS OXIDASE AND CALCIUM ANTAGONISTS AND THEIR USE.
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业(广州)有限公司 Compound preparation of lercanidipine and atorvastatin
CN105758967B (en) * 2016-03-24 2017-10-27 中国药科大学 The mark group of coronary atherosclerosis and stable angina cordis is distinguished in diagnosis
CN110915354B (en) * 2019-12-05 2021-11-23 重庆市农业科学院 Automatic dicer of seed potato
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879303A (en) * 1986-04-04 1989-11-07 Pfizer Inc. Pharmaceutically acceptable salts
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US20070282915A1 (en) * 2006-03-31 2007-12-06 Vosshall Peter S System and method for providing high availability data

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (en) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (en) 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
DK161312C (en) * 1982-03-11 1991-12-09 Pfizer CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3807895A1 (en) 1988-03-10 1989-09-21 Knoll Ag PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER
US4804770A (en) 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
US5273985A (en) * 1988-07-04 1993-12-28 Eisai Co., Ltd. Glycerin derivative and its pharmacological use
MY105067A (en) 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
US4920123A (en) 1988-10-21 1990-04-24 Beyer Jr Karl H Method for controlling and/or lowering serum triglyceride and/or cholesterol levels in mammals
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5155120A (en) * 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
DE4309553A1 (en) 1993-03-24 1994-09-29 Bayer Ag Process for the preparation of 3R, 5S - (+) - sodium erythro- (E) -7- (4- (4-flurophenyl) -2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl) -3, 5-dihydroxy-hept-6-enoate
IN176897B (en) 1993-10-29 1996-09-28 Cadila Lab Ltd
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5447922A (en) 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
EP0738510A3 (en) 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
DE19539363A1 (en) 1995-10-23 1997-04-24 Basf Ag Process for the production of solid dosage forms
UA46069C2 (en) * 1995-11-02 2002-05-15 Варнер-Ламберт Компані PROFILE NORMALIZATION METHOD LIPOPROTEYIDNOHO blood plasma of mammals pharmaceutical composition for its implementation, a method for preventing and / or treating diseases associated with dysfunction of the endothelium, a way to restore activity caused by endogenous vascular endothelium, the way STABILIZATION AND PREVENTION atherosclerotic plaques in mammals GAP
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.
GT199800127A (en) * 1997-08-29 2000-02-01 THERAPEUTIC COMBINATIONS.
DK1180102T3 (en) * 1999-05-27 2004-09-06 Pfizer Prod Inc Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (en) * 1999-05-27 2001-02-02 Pfizer Prod Inc MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA
US20030092745A1 (en) * 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879303A (en) * 1986-04-04 1989-11-07 Pfizer Inc. Pharmaceutically acceptable salts
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US20070282915A1 (en) * 2006-03-31 2007-12-06 Vosshall Peter S System and method for providing high availability data

Also Published As

Publication number Publication date
GEP20104874B (en) 2010-01-11
US20060223865A1 (en) 2006-10-05
DE69835245D1 (en) 2006-08-24
HUP0003656A2 (en) 2001-03-28
US20040048906A1 (en) 2004-03-11
US20120208854A1 (en) 2012-08-16
PE107199A1 (en) 1999-11-06
NO320267B1 (en) 2005-11-14
EA003549B1 (en) 2003-06-26
EP1003503A1 (en) 2000-05-31
TR200000561T2 (en) 2000-07-21
HUP0003656A3 (en) 2002-10-28
ZA987844B (en) 2000-02-28
US20030008904A1 (en) 2003-01-09
AP9801334A0 (en) 1998-09-30
AU755636B2 (en) 2002-12-19
PL192360B1 (en) 2006-10-31
BG104177A (en) 2000-12-29
PT1491193E (en) 2006-10-31
SK284958B6 (en) 2006-03-02
US6455574B1 (en) 2002-09-24
CA2301732A1 (en) 1999-03-11
PA8457101A1 (en) 2000-05-24
CZ301081B6 (en) 2009-10-29
RS50485B (en) 2010-03-02
ME00545B (en) 2011-10-10
US20090297598A1 (en) 2009-12-03
DE69835245T2 (en) 2007-07-19
DE69826683D1 (en) 2004-11-04
AP1225A (en) 2003-11-20
YU2100A (en) 2002-11-15
BG64665B1 (en) 2005-11-30
US20100168187A1 (en) 2010-07-01
EP1468682A1 (en) 2004-10-20
MY123993A (en) 2006-06-30
OA11290A (en) 2003-08-25
DZ2596A1 (en) 2003-02-22
MA26535A1 (en) 2004-12-20
CZ2000511A3 (en) 2000-06-14
CN101062035A (en) 2007-10-31
IS5343A (en) 2000-01-14
LU91253I2 (en) 2006-08-21
ES2266961T3 (en) 2007-03-01
SK2042000A3 (en) 2000-12-11
KR20010023498A (en) 2001-03-26
IS2029B (en) 2005-08-15
IL134303A0 (en) 2001-04-30
UY25157A1 (en) 2000-12-29
PL339092A1 (en) 2000-12-04
EP1491193A1 (en) 2004-12-29
DK1003503T3 (en) 2005-01-10
DE69826683T2 (en) 2005-10-20
CY1105108T1 (en) 2010-03-03
DK1491193T3 (en) 2006-10-16
AR012269A1 (en) 2000-09-27
WO1999011259A1 (en) 1999-03-11
CN1268052A (en) 2000-09-27
JP2001514222A (en) 2001-09-11
JP2010111693A (en) 2010-05-20
EP1491193B1 (en) 2006-07-12
US20130131125A1 (en) 2013-05-23
ES2227865T3 (en) 2005-04-01
NO20000998D0 (en) 2000-02-28
SI1003503T1 (en) 2004-12-31
IL134303A (en) 2006-10-05
US20140039017A1 (en) 2014-02-06
UA71897C2 (en) 2005-01-17
EP1003503B1 (en) 2004-09-29
CA2301732C (en) 2005-03-29
EA200000164A1 (en) 2000-10-30
SI1491193T1 (en) 2006-10-31
HRP980473B1 (en) 2005-10-31
JP2004210797A (en) 2004-07-29
TNSN98156A1 (en) 2005-03-15
HRP980473A2 (en) 1999-06-30
PT1003503E (en) 2004-12-31
ATE277615T1 (en) 2004-10-15
NO20000998L (en) 2000-02-28
GEP20084338B (en) 2008-03-25
CY2007003I1 (en) 2009-11-04
HN1998000132A (en) 1999-02-09
CO4970694A1 (en) 2000-11-07
TW592696B (en) 2004-06-21
ATE332689T1 (en) 2006-08-15
NZ537880A (en) 2007-04-27
ID23670A (en) 2000-05-11
NZ527158A (en) 2005-03-24
BR9812030A (en) 2000-09-26
US20060270717A1 (en) 2006-11-30
GT199800127A (en) 2000-02-01
AU8554898A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
US6455574B1 (en) Therapeutic combination
AP1207A (en) Combination therapy.
US6262092B1 (en) Mutual salt of amlodipine and atorvastatin
US20070149578A1 (en) Combination Therapy
MXPA00002087A (en) Therapeutic combinations comprising amlodipin and atorvastatin
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION